We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 24, 2022

SUVmax Determined Using PSMA PET/CT Is Associated With Oncological Outcomes in Patients With Prostate Cancer

BJU International


Additional Info

Disclosure statements are available on the authors' profiles:

BJU International
Standardised uptake values as determined on prostate-specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer
BJU Int 2022 Jun 01;129(6)768-776, YJL Bodar, H Veerman, D Meijer, K de Bie, PJ van Leeuwen, ML Donswijk, RJA van Moorselaar, NH Hendrikse, R Boellaard, DE Oprea-Lager, AN Vis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading